Table 1.
Clinical data characteristics of three age groups of COVID-19 patients
| Groups | All patients (n = 307) | Age < 40 Y (n = 104) | 40 Y ≤ Age <60 Y (n = 137) | 60 Y ≤ Age (n = 66) | P1(G1 & G2) | P2(G1 &G3) | P3(G2 &G3) |
|---|---|---|---|---|---|---|---|
| CBI | |||||||
| Sex (male, %) | 156 (50.8%) | 53 (51%) | 72 (52.6%) | 31 (47%) | 0.806 | 0.612 | 0.456 |
| Age (M ± SD, Y) (Rang, Y) | 46.2 ± 17.11 (1 ~ 89) | 2.3 ± 8.35 (1 ~ 39) | 49.3 ± 5.35 (40 ~ 59) | 69.3 ± 8.51 l(60 ~ 89) | / | / | / |
| HD | |||||||
| Hypertension | 31 (10.1%) | 0 | 16 (11.7%) | 15 (22.7%) | <0.001 | <0.001 | 0.040 |
| Diabetes | 15 (4.9%) | 0 | 9 (6.6%) | 6 (9.1%) | 0.020 | 0.007 | 0.721 |
| Hepatitis B | 8 (2.6%) | 1 (1%) | 7 (5.1%) | 0 | 0.156 | 1.000 | 0.145 |
| COPD | 3 (1%) | 0 | 0 | 3 (4.5%) | 1.000 | 0.058 | 0.110 |
| Clinical symptoms | |||||||
| Fever | 301 (98%) | 100 (96.2%) | 135 (98.5%) | 66 (100%) | 0.447 | 0.274 | 0.820 |
| Cough | 239 (77.9%) | 79 (76%) | 101 (73.7%) | 59 (89.4%) | 0.692 | 0.029 | 0.010 |
| Fatigue | 51 (16.6%) | 13 (12.5%) | 23 (16.8%) | 15 (22.7%) | 0.355 | 0.080 | 0.310 |
| Sore throat | 37 (12.1%) | 14 (13.5%) | 14 (10.2%) | 9 (13.6%) | 0.453 | 0.955 | 0.472 |
| Chest tightness or pain | 34 (11.1%) | 6 (5.8%) | 12 (8.8%) | 16 (24.2%) | 0.382 | <0.001 | 0.003 |
| Dizziness or pain | 28 (9.1%) | 8 (7.7%) | 13 (9.5%) | 7 (10.6%) | 0.624 | 0.514 | 0.802 |
| Aching muscles | 27 (8.8%) | 5 (4.8%) | 15 (10.9%) | 7 (10.6%) | 0.087 | 0.258 | 0.941 |
| Hyperpnea | 21 (6.8%) | 3 (2.9%) | 10 (7.3%) | 8 (12.1%) | 0.133 | 0.039 | 0.258 |
| Nasal stuffiness | 20 (6.5) | 8 (7.7%) | 11 (8%) | 1 (1.5%) | 0.923 | 0.161 | 0.127 |
| Others# | 8 (2.6%) | 2 (1.9%) | 3 (2.2%)) | 3 (4.5%) | 1.000 | 0.603 | 0.627 |
| LE | |||||||
| CRP increase | 182 (59.3%) | 47 (45.2%) | 93 (67.9%) | 42 (63.6%) | <0.001 | 0.019 | 0.548 |
| LY% abnormal | 148 (48.2%) | 35 (33.7%)6↑ | 71 (51.8%)1↑ | 42 (63.6%) | 0.005 | <0.001 | 0.113 |
| NEUT% abnormal | 95 (30.9%) | 21 (20.2%)5↓ | 43 (31.4%)3↓ | 31 (47%) | 0.051 | <0.001 | 0.031 |
| MO% abnormal | 70 (22.8%) | 31 (29.8%)2↓ | 33 (24.1%) | 6 (9.1%) | 0.319 | 0.001 | 0.011 |
| WBC% abnormal | 60 (19.5%) | 19 (18.3%)2↑ | 21 (15.3%)4↑ | 20 (30.3%)9↑ | 0.543 | 0.069 | 0.013 |
| Clinical types | 0.002 | <0.001 | 0.015 | ||||
| Mild/Moderate | 259 (84.6%) | 100 (96.2%) | 114 (83.2%) | 45 (68.2%) | |||
| Severe/Critical | 48 (15.6%) | 4 (3.8%) | 23 (16.8%) | 21 (31.8%) | |||
| HEE | 114 (37.1%) | 49 (47.1%) | 56 (40.9%) | 9 (13.6%) | 0.333 | <0.001 | <0.001 |
Note: Y years, G1 Age<40 Y, G2 40 Y ≤ Age<60 Y, G3 60 Y ≤ Age, CBI Clinical baseline information, COPD chronic obstructive pulmonary disease, HD History of disease, LE laboratory examination; CRP: C-reactive protein (normal: 0 ~ 10 mg/); WBC: white blood cell (normal: 3.5 ~ 9.5 × 109), Ly lymphocyte (normal: 20% ~ 40%), Mo monocyte (normal: 3 ~ 10%), NEUT neutrophil (normal: 40% ~ 75%), HEE history of epidemiological exposure, Others* Major diseases or surgical history, Others# diarrhoea or vomiting